Trial record 2 of 11 for:    pulmonx

To Improve Lung Function and Symptoms for Emphysema Patients Using Zephyr EBV (TRANSFORM)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT02022683
Recruitment Status : Active, not recruiting
First Posted : December 30, 2013
Last Update Posted : April 7, 2017
Information provided by (Responsible Party):
Pulmonx, Inc.

Brief Summary:
To compare the clinical outcomes of Endoscopic Lung Volume Reduction using Pulmonx Zephyr Endobronchial Valve (EBV) vs. Standard of Care (SoC) in the treatment of heterogeneous emphysema patients in a controlled trial design setting.

Condition or disease Intervention/treatment Phase
COPD Heterogeneous Emphysema Device: ELVR (Endoscopic Lung Volume Reduction) with Zephyr valve Not Applicable

Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 97 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: A Multi-center, Prospective, Randomized, Controlled Trial of Endobronchial Valve Therapy vs. Standard of Care in Heterogeneous Emphysema
Study Start Date : December 2013
Actual Primary Completion Date : December 2016
Estimated Study Completion Date : December 2018

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Emphysema Endoscopy

Arm Intervention/treatment
Experimental: Endoscopic Lung Volume Reduction
Patients are implanted Zephyr EBV
Device: ELVR (Endoscopic Lung Volume Reduction) with Zephyr valve
Standard Medical Care

No Intervention: Standard of Care
Patients are given Standard of Care treatment

Primary Outcome Measures :
  1. Change in FEV1 [ Time Frame: Between baseline and 3 months ]

Secondary Outcome Measures :
  1. Changes in St George's Respiratory Questionnaire, 6-Min Walk Test, BODE index, mMRC score, [ Time Frame: Betwenn baseline and 3, 6, 12, 18, and 24 months ]

Other Outcome Measures:
  1. Changes in Target Lobar Volume Reduction (TLVR), Residual Volume, EQ-5D summary index, AEs and SAEs, paO2 [ Time Frame: Change in TLVR between baseline and 45 days ]

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Ages Eligible for Study:   40 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Heterogeneous emphysema
  • 15% pred < or = FEV1 < or = 45% pred
  • TLC > 100% and RV > or = 180%
  • 150 m < or = 6MWT < or = 450 m
  • No collateral ventilation

Exclusion Criteria:

  • Contraindication to bronchoscopy
  • Active pulmonary infection
  • History of 2 or more exacerbations with hospitalization over the past 12 months
  • Known pulmonary hypertension
  • Prior LVR or LVRS procedure
  • Pregnant or lactating woman
  • Hypercapnia
  • Current diagnosis of asthma
  • > 25 mg Prednisolon / day
  • CV in the target lobe or inconclusive Chartis assessment

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT02022683

Universiteit Gent
Gent, Belgium, 9000
AZ Delta
Menen, Belgium, 8930
Grenoble, France, 38043
CHU Hôpital Pasteur
Nice, France, 06002
Groupe Hospitalier Pitié Salpétrière
Paris, France, 75013
Hôpital Bichat Claude Bernard
Paris, France, 75877
Charité Campus Virchow-Klinikum
Berlin, Germany, 13353
Ruhrlandklinik Westdeutsches Lungenzentrum
Essen, Germany, 45239
Thoraxklinik am Universitäts Klinikum Heidelberg
Heidelberg, Germany, 69126
University Medical Center Groningen
Groningen, Netherlands, 9700
Skane University Hospital
Lund, Sweden, 221 85
Uppsala University Hospital
Uppsala, Sweden, 751 85
United Kingdom
Sherwood Forest Hospitals NHS
Sutton in Ashfield, Nottinghamshire, United Kingdom, NG17 4JL
West of Scotland Regional Heart & Lung Centre - Golden Jubilee National Hospital
West Dunbartonshire, West Dunbartonshire Scotland, United Kingdom, G81 4DY
University Hospital of Wales
Cardiff, United Kingdom, CF144XW
The Royal Brompton Hospital & Harefield NHS Foundation Trust
London, United Kingdom, SW3 6NP
Sheffield Teaching Hospitals NHS Foundation Trust
Sheffield, United Kingdom, S5 7AU
Sponsors and Collaborators
Pulmonx, Inc.
Principal Investigator: Gunnar Hillerdal, MD, PhD Uppsala University Hospital Sweden

Publications automatically indexed to this study by Identifier (NCT Number):
Responsible Party: Pulmonx, Inc. Identifier: NCT02022683     History of Changes
Other Study ID Numbers: 630-0015/A
First Posted: December 30, 2013    Key Record Dates
Last Update Posted: April 7, 2017
Last Verified: April 2017

Keywords provided by Pulmonx, Inc.:
Endoscopic lung volume reduction
Endobronchial valves

Additional relevant MeSH terms:
Pulmonary Emphysema
Pathologic Processes
Pulmonary Disease, Chronic Obstructive
Lung Diseases, Obstructive
Lung Diseases
Respiratory Tract Diseases